Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study

Novartis

Status

Completed

Conditions

Psoriatic Arthritis

Axial Spondyloarthritis

Treatments

Drug: secukinumab

Study type

Observational

Funder types

Industry

Identifiers

NCT05677542

CAIN457FES07

Details and patient eligibility

About

This was a multicenter, retrospective, and non-interventional study using secondary data captured in the Electronic Health Records (EHRs). The extraction of the data captured in the EHRs was performed with EHRead® by SAVANA, an innovating data-driven system based on Natural Language Processing (NLP) and big data analytics. Data was extracted and analyzed at Index Date, Follow Up, or as specified for each variable.

Enrollment

758 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged ≥ 18 years.
Diagnosed with axSpA or PsA.
Had received or are receiving bDMARD, independently of the line of treatment, from January 2018 to data collection.
Had at least 3 months follow up from first bDMARD administration.
Patients with EHRs.

Exclusion criteria

• Receiving bDMARD within a clinical trial from January 2018 to data collection.